Summary
- Current Price
- As of today, ARGX price is $851.29, down -0.66% on
- Current Price All-Time High
- ARGX price is currently -10.73% below its historical high of $953.58 set on
- Market Cap
- ARGX current market cap is $53B, up +32.59% over the past 365 days
- Revenue
- ARGX current annual revenue is $4.17B, up +90.56% year-over-year
- Next Earnings
- The next earnings release for ARGX is on
Profile
| Metric | Value |
|---|---|
| Full Name | argenx SE |
| Ticker | NASDAQ: ARGX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Netherlands |
| IPO | |
| Indexes | Not included |
| Website | argenx.com |
| Employees | 1,599 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $851.29 | |
| Price, 1D Change | -0.66% | |
| Market Cap | $53B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.36 | |
| Revenue | $4.17B | |
| Revenue, 1Y Change | +90.56% | |
| EPS | $19.63 | |
| EPS, 1Y Change | +53.84% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $19.63 | |
| EPS Estimate | $28.45 | N/A |
| EPS Est. Change | +44.95% | N/A |
| Revenue | $4.17B | |
| Revenue Estimate | $6.20B | N/A |
| Revenue Est. Change | +48.76% | N/A |
| Current Price | $851.29 | |
| Price Target | $1,067.00 | - |
| Price Tgt. Change | +25.34% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.32 | $12.76 | +449.82% | |
| $15.11 | $19.63 | +29.86% | |
| $28.45 | N/A | +44.95% | |
| $39.56 | N/A | +101.53% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $2.09B | $2.19B | +4.69% | |
| $3.59B | $4.17B | +16.21% | |
| $6.20B | N/A | +48.76% | |
| $7.61B | N/A | +82.67% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +30.48% | |
| Price, 3Y | +67.92% | |
| Market Cap, 1Y | +32.59% | |
| Market Cap, 3Y | +78.39% | |
| Revenue, 1Y | +90.56% | |
| Revenue, 3Y | +913.78% | |
| EPS, 1Y | +53.84% | |
| EPS, 3Y | +250.34% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $851.29 | |
| SMA 200 | $831.53 | |
| SMA 50 | $879.02 | |
| EMA 200 | $812.19 | |
| EMA 50 | $864.33 | |
| MACD | -$4.78 | |
| Beta | 0.36 | |
| ATR | $26.69 | |
| 14-Day RSI | 45.38 | |
| 10-Day Volatility | 29.18% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $4.17B | |
| EPS | $19.63 | |
| Gross Profit | $3.71B | |
| Gross Margin | 89.14% | |
| Operating Income | $993.75M | |
| Operating Margin | 23.85% | |
| Net Income | $1.30B | |
| Net Margin | 31.11% | |
| EBITDA | $1.02B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.01 | |
| 5.23 | ||
| 4.87 | ||
| - | ||
| - | ||
| 24.95 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | - | |
| 10.13 | ||
| 6.49 | ||
| 27.93 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $7.32B | |
| $4.44B | ||
| $8.68B | ||
| $6.90B | ||
| $1.36B | ||
| $1.32B | ||
| Total Debt | $47.16M | |
| $10.83M | ||
| $1.27B |
Expenses
| Metric | Value | Date |
|---|---|---|
| $2.87B | ||
| $2.70B | ||
| $471.94M | ||
| $1.37B | ||
| $28.19M | ||
| $0.00 | ||
| -$76.17M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $850.49M | ||
| $823.88M | ||
| $233.73M | ||
| Capex | $112.03M | |
| $738.46M |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Wedbush | → | |
| Baird | → | |
| RBC Capital | → | |
| Oppenheimer | → | |
| Guggenheim | → | |
| Citizens | → | |
| Citigroup | → | |
| RBC Capital | → | |
| B of A Securities | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with ARGX
FAQ
- What is the ticker symbol for argenx SE?
- The ticker symbol for argenx SE is NASDAQ:ARGX
- Does argenx SE pay dividends?
- No, argenx SE does not pay dividends
- What sector is argenx SE in?
- argenx SE is in the Healthcare sector
- What industry is argenx SE in?
- argenx SE is in the Biotechnology industry
- What country is argenx SE based in?
- argenx SE is headquartered in Netherlands
- When did argenx SE go public?
- argenx SE initial public offering (IPO) was on May 18, 2017
- Is argenx SE in the S&P 500?
- No, argenx SE is not included in the S&P 500 index
- Is argenx SE in the NASDAQ 100?
- No, argenx SE is not included in the NASDAQ 100 index
- Is argenx SE in the Dow Jones?
- No, argenx SE is not included in the Dow Jones index
- When was argenx SE last earnings report?
- argenx SE's most recent earnings report was on July 23, 2026
- When does argenx SE report earnings?
- The next expected earnings date for argenx SE is October 22, 2026
Data Sources & References
- ARGX Official Website argenx.com
- ARGX Profile on Yahoo Finance finance.yahoo.com/quote/ARGX
- ARGX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/argx